S-1联合顺铂或奥沙利铂化疗后转化手术治疗不可切除胃癌的疗效
Efficacy of Conversion Surgery Following S-1 plus Cisplatin or Oxaliplatin Chemotherapy for Unresectable Gastric Cancer.
作者信息
Fukuchi Minoru, Mochiki Erito, Ishiguro Toru, Ogura Toshiro, Sobajima Jun, Kumagai Youichi, Ishibashi Keiichiro, Ishida Hideyuki
机构信息
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
出版信息
Anticancer Res. 2017 Mar;37(3):1343-1347. doi: 10.21873/anticanres.11453.
BACKGROUND/AIM: To evaluate the efficacy of conversion surgery following S-1 plus cisplatin (CS) or oxaliplatin (SOX) chemotherapy.
PATIENTS AND METHODS
We retrospectively analyzed clinicopathological and survival data of 74 patients with unresectable gastric cancer receiving CS or SOX.
RESULTS
Fifty-five and nineteen patients received CS and SOX, respectively. Conversion surgery (odds ratio (OR), 0.17; 95% confidence interval (CI), 0.04-0.64; p=0.01) was the only significant independent predictor of longer survival in multivariate Cox regression analysis. Patients (median age, 74 years) receiving SOX were significantly older than those receiving CS (median age=67 years) (p<0.01), although the rates of response, severe toxicity or conversion surgery did not differ significantly between the two treatment groups.
CONCLUSION
Conversion surgery after a response to CS or SOX chemotherapy may have survival benefit in selected unresectable gastric cancer patients, for both non-elderly and elderly patients responding to SOX.
背景/目的：评估S-1联合顺铂（CS）或奥沙利铂（SOX）化疗后进行转化手术的疗效。
患者与方法
我们回顾性分析了74例接受CS或SOX治疗的不可切除胃癌患者的临床病理和生存数据。
结果
分别有55例和19例患者接受了CS和SOX治疗。在多因素Cox回归分析中，转化手术（比值比（OR），0.17；95%置信区间（CI），0.04 - 0.64；p = 0.01）是生存时间延长的唯一显著独立预测因素。接受SOX治疗的患者（中位年龄74岁）比接受CS治疗的患者（中位年龄67岁）年龄显著更大（p < 0.01），尽管两个治疗组之间的缓解率、严重毒性或转化手术率没有显著差异。
结论
对于部分不可切除的胃癌患者，CS或SOX化疗有效后进行转化手术可能对生存有益，包括对SOX有反应的非老年和老年患者。
Zotero 插件